Skip to content

NAD+evidence-first

The NAD Review
menu

evidence_review

Nicotinamide Riboside (NR) Side Effects: What the Trials Show

Nicotinamide riboside (NR) was well tolerated in human RCTs — mostly mild GI effects, no serious signal — but long-term NR safety isn't fully established.

Nicotinamide riboside (NR) is the NAD+ precursor inside the most-marketed branded supplements — Niagen, and the Tru Niagen products built on it. So when people search "nicotinamide riboside side effects," they're usually really asking about the safety of a pill millions of people take daily. The honest answer is encouraging but bounded: in the human randomized controlled trials run so far, NR has been well tolerated, with side effects that are mostly mild and gastrointestinal and no serious safety signal at the doses studied. What that record does not prove is that daily NR is "safe forever." The trials are months-long and modest-sized, so "well tolerated short-term" is a genuinely different claim from "proven safe over years."

This page lays out what the human NR trials actually report, the doses behind that reassurance, and where the evidence honestly runs out.

What the human trials report

NR has one of the cleaner short-term safety records among NAD+ precursors, largely because it was studied carefully and early. The foundational result comes from a 2018 placebo-controlled crossover trial in healthy middle-aged and older adults: chronic NR supplementation was well tolerated and elevated NAD+ without a serious adverse-event signal 1. That's the clean baseline — NR does the biochemical job it's sold for, and it did so without alarming the safety monitors.

The most safety-focused study, though, is the one built specifically to ask the tolerability question. Conze, Brenner, and Kruger (2019) ran a randomized, double-blind, placebo-controlled trial in healthy overweight adults explicitly to evaluate the safety and metabolism of long-term administration of NIAGEN — the commercial nicotinamide riboside chloride 2. Across eight weeks at up to 1,000 mg/day, NR was well tolerated; reported effects were mild and didn't differ meaningfully from placebo in any way that raised a red flag. That study is why "NIAGEN is well tolerated" is a defensible statement rather than marketing.

// What the NR safety data does and doesn't establish

  • Short-term tolerability (weeks–months)[ MODERATE ]

    Human RCTs, incl. a purpose-built NIAGEN safety trial: well tolerated, mostly mild GI effects, no serious signal at ~250–1,000 mg/day.

  • Long-term, multi-year safety[ NONE ]

    No trials of that duration exist — genuinely unestablished.

  • Safety of megadosing above studied amounts[ NONE ]

    Beyond where the reassuring trial data ends.

  • Safety in special populations[ NONE ]

    Pregnancy, cancer history, polypharmacy — essentially unstudied; ask a clinician.

Tiers reflect the human-trial safety evidence, not marketing. NR looks well tolerated short-term — including a dedicated NIAGEN safety study — but long-term, high-dose, and special-population safety simply has not been established.

When side effects are reported in NR trials, they're the unremarkable kind you'd expect from many oral supplements:

  • Gastrointestinal upset — nausea, indigestion, bloating, stomach discomfort, or loose stools are the effects mentioned most often, usually mild and often at rates close to placebo.
  • Mild, non-specific symptoms — headache, fatigue, or transient flushing turn up occasionally in individual reports.

NR is a form of vitamin B3, but it is not nicotinic acid (niacin), so it generally does not cause the classic, uncomfortable "niacin flush." (For how the side-effect picture shifts across delivery routes — oral precursors versus IV drips versus injections — see our NAD+ side effects guide.)

The doses behind the reassurance

"Well tolerated" is only meaningful with the dose and duration attached. The human NR trials generally tested roughly 250 to 1,000 mg per day over windows of a few weeks to a few months. The 2018 chronic-dosing trial and the 2019 NIAGEN safety study both sit inside that range 1 2, and that's where the reassurance applies. It does not automatically extend to the open-ended, "more is better" megadosing common in longevity circles, where intakes climb well above what was ever tested and continue indefinitely. That's exactly the territory where the trial data stops covering you.

So the practical read is: the comfortable safety profile is dose- and duration-bounded. NR at label doses for weeks to months looks reassuring; NR at multiples of that, taken for years, is simply not what the trials measured.

Where the evidence honestly runs out

Here's the part the supplement copy tends to skip. Even NR's best safety studies are months long, in modest numbers of mostly healthy adults. That design tells you about weeks-to-months tolerability — it cannot tell you what daily NR does over five or ten years, because no trial has run that long. "No serious signal in an eight-week study" is real and worth knowing; it is not the same as "proven safe for a decade of daily use." Anyone selling you the second claim by pointing at evidence for the first is overstating their hand.

Two more honest caveats:

  • Special populations are essentially unstudied. Pregnancy, breastfeeding, active or prior cancer, and people on multiple prescription medications were not the populations these trials recruited, so the reassurance doesn't cleanly transfer to them. The theoretical NAD+/tumor-metabolism question, in particular, is unresolved rather than settled — we treat it carefully in our NAD+ side effects guide, and it's a real reason for caution with a personal or family cancer history.
  • What's in the bottle isn't guaranteed. Even with a relatively well-regulated, branded ingredient like Niagen, product quality varies across the broader NR market. Some real-world "NR side effects" may reflect a poorly made product rather than the molecule itself — an argument for choosing on third-party testing rather than price, which is how we rank in the best NAD+ supplements, rated by evidence.

NR versus NMN on safety

If you're weighing precursors, NR's safety record is its quiet strength: it has more dedicated tolerability data behind it than most alternatives, including the purpose-built NIAGEN study. NMN's short-term safety record is similarly reassuring but, like NR's, is bounded by short trials. Neither precursor has long-term human safety nailed down — we lay the two side by side, including how their benefit evidence compares, in NMN vs NR, and cover NMN's own profile in NMN side effects. If your interest is specifically the branded NR product most people actually buy, we put its full trial record under the microscope in our Tru Niagen review.

The honest bottom line

NR's safety story in the human trials so far is genuinely reassuring but narrow: mostly mild, mostly GI, no serious signal, at the doses and durations studied — and with a purpose-built NIAGEN safety trial backing the most-sold version. What that record does not do is prove daily NR is safe for years, cover megadoses well above what was tested, settle special-population questions, or guarantee the contents of every bottle. Treat "well tolerated short-term" as exactly that.

This is consumer education, not medical advice. NR is sold as a dietary supplement and is not FDA-approved to treat any disease. If you're pregnant, have a medical condition, or take other medications, talk to a clinician before starting NR — and to model doses and timing honestly, see our tools.

Frequently asked questions

Is nicotinamide riboside (NR) safe?

In the human randomized trials run so far, NR has been well tolerated, with mostly mild gastrointestinal effects and no serious safety signal at the doses studied (roughly 250–1,000 mg/day). A 2019 trial specifically evaluated the safety and metabolism of long-term NIAGEN (nicotinamide riboside chloride) dosing and found it well tolerated. But those trials are months-long and modest-sized, so they establish short-term tolerability — not multi-year safety. 'Well tolerated short-term' is not the same as 'proven safe forever.'

What are the most common NR side effects?

When side effects are reported, they're usually mild and gastrointestinal — nausea, indigestion, bloating, stomach discomfort, or loose stools — often at rates similar to placebo. Mild, non-specific effects like headache, fatigue, or flushing turn up occasionally. NR is a form of vitamin B3 but not nicotinic acid, so it generally does not cause the classic 'niacin flush.'

How much NR is considered safe to take?

Human trials have generally tested NR in the roughly 250–1,000 mg/day range over weeks to a few months and reported good tolerability within that window. That reassurance is bounded by the doses and durations actually studied — it does not extend to megadosing well above those amounts or to taking high doses indefinitely, which is exactly where the evidence runs out.

Is the long-term safety of NR established?

No. Even NR's best safety studies, including the purpose-built NIAGEN trial, run for months in modest numbers of mostly healthy adults. That design tells you about weeks-to-months tolerability — no trial has followed daily NR for years, so multi-year safety is genuinely unestablished. The reassuring short-term record should not be read as proof of long-term safety.

Who should be cautious with NR?

Because long-term and special-population data is thin, NR is best treated as a talk-to-a-clinician-first product if you're pregnant or breastfeeding, have active or prior cancer (given the unresolved NAD+/tumor-metabolism question), or take multiple prescription medications. These groups were not the populations the trials recruited, so the short-term reassurance doesn't cleanly transfer to them.

References

  1. Martens CR, Denman BA, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/29599478/
  2. Conze D, Brenner C, Kruger CL (2019). Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/31278280/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

continue_reading